177 related articles for article (PubMed ID: 32972352)
1. Clinical and
Ilkhani K; Delgir S; Safi A; Seif F; Samei A; Bastami M; Alivand MR
Anticancer Agents Med Chem; 2021; 21(7):927-935. PubMed ID: 32972352
[TBL] [Abstract][Full Text] [Related]
2. Plasma-based microRNA signatures in early diagnosis of breast cancer.
Li X; Zou W; Wang Y; Liao Z; Li L; Zhai Y; Zhang L; Gu S; Zhao X
Mol Genet Genomic Med; 2020 May; 8(5):e1092. PubMed ID: 32124558
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of NRARP exerts anti-tumor activities in the breast tumor cells depending on Wnt/β-catenin-mediated signals: The role of miR-130a-3p.
Poodineh J; Sirati-Sabet M; Rajabibazl M; Ghasemian M; Mohammadi-Yeganeh S
Chem Biol Drug Des; 2022 Sep; 100(3):334-345. PubMed ID: 35797350
[TBL] [Abstract][Full Text] [Related]
4. Deregulation of miR-1245b-5p and miR-92a-3p and their potential target gene, GATA3, in epithelial-mesenchymal transition pathway in breast cancer.
Yadollahi Farsani M; Amini Farsani Z; Teimuri S; Kolahdouzan M; Eshraghi Samani R; Teimori H
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1955. PubMed ID: 38173189
[TBL] [Abstract][Full Text] [Related]
5. Aberrant expression of a five-microRNA signature in breast carcinoma as a promising biomarker for diagnosis.
Bitaraf A; Babashah S; Garshasbi M
J Clin Lab Anal; 2020 Feb; 34(2):e23063. PubMed ID: 31595567
[TBL] [Abstract][Full Text] [Related]
6. Downregulated lncRNA ADAMTS9-AS2 in breast cancer enhances tamoxifen resistance by activating microRNA-130a-5p.
Shi YF; Lu H; Wang HB
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1563-1573. PubMed ID: 30840279
[TBL] [Abstract][Full Text] [Related]
7. Identification of a six-microRNA signature as a potential diagnostic biomarker in breast cancer tissues.
Mahmoudian M; Razmara E; Mahmud Hussen B; Simiyari M; Lotfizadeh N; Motaghed H; Khazraei Monfared A; Montazeri M; Babashah S
J Clin Lab Anal; 2021 Nov; 35(11):e24010. PubMed ID: 34528314
[TBL] [Abstract][Full Text] [Related]
8. A Signature of Four Circulating microRNAs as Potential Biomarkers for Diagnosing Early-Stage Breast Cancer.
Itani MM; Nassar FJ; Tfayli AH; Talhouk RS; Chamandi GK; Itani ARS; Makoukji J; Boustany RN; Hou L; Zgheib NK; Nasr RR
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34204158
[TBL] [Abstract][Full Text] [Related]
9. MiR-182-5p Knockdown Targeting PTEN Inhibits Cell Proliferation and Invasion of Breast Cancer Cells.
Zhao YS; Yang WC; Xin HW; Han JX; Ma SG
Yonsei Med J; 2019 Feb; 60(2):148-157. PubMed ID: 30666836
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of exosomal miRNAs between breast cancer patients with and without recurrence.
Sueta A; Yamamoto Y; Tomiguchi M; Takeshita T; Yamamoto-Ibusuki M; Iwase H
Oncotarget; 2017 Sep; 8(41):69934-69944. PubMed ID: 29050253
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA Expression Profiling on Paired Primary and Lymph Node Metastatic Breast Cancer Revealed Distinct microRNA Profile Associated With LNM.
Elango R; Alsaleh KA; Vishnubalaji R; Manikandan M; Ali AM; Abd El-Aziz N; Altheyab A; Al-Rikabi A; Alfayez M; Aldahmash A; Alajez NM
Front Oncol; 2020; 10():756. PubMed ID: 32509578
[TBL] [Abstract][Full Text] [Related]
12. Regulation of UHRF1 by dual-strand tumor-suppressor microRNA-145 (miR-145-5p and miR-145-3p): Inhibition of bladder cancer cell aggressiveness.
Matsushita R; Yoshino H; Enokida H; Goto Y; Miyamoto K; Yonemori M; Inoguchi S; Nakagawa M; Seki N
Oncotarget; 2016 May; 7(19):28460-87. PubMed ID: 27072587
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA profiling in serum: Potential signatures for breast cancer diagnosis.
Zou X; Xia T; Li M; Wang T; Liu P; Zhou X; Huang Z; Zhu W
Cancer Biomark; 2021; 30(1):41-53. PubMed ID: 32894240
[TBL] [Abstract][Full Text] [Related]
14. LncRNA H19 interacted with miR-130a-3p and miR-17-5p to modify radio-resistance and chemo-sensitivity of cardiac carcinoma cells.
Jia J; Zhang X; Zhan D; Li J; Li Z; Li H; Qian J
Cancer Med; 2019 Apr; 8(4):1604-1618. PubMed ID: 30843379
[TBL] [Abstract][Full Text] [Related]
15. Identification and validation of miR-583 and mir-877-5p as biomarkers in patients with breast cancer: an integrated experimental and bioinformatics research.
Foruzandeh Z; Alivand MR; Ghiami-Rad M; Zaefizadeh M; Ghorbian S
BMC Res Notes; 2023 May; 16(1):72. PubMed ID: 37158948
[TBL] [Abstract][Full Text] [Related]
16. MiR-130a-3p inhibits migration and invasion by regulating RAB5B in human breast cancer stem cell-like cells.
Kong X; Zhang J; Li J; Shao J; Fang L
Biochem Biophys Res Commun; 2018 Jun; 501(2):486-493. PubMed ID: 29746865
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer.
Ouyang M; Li Y; Ye S; Ma J; Lu L; Lv W; Chang G; Li X; Li Q; Wang S; Wang W
PLoS One; 2014; 9(5):e96228. PubMed ID: 24788655
[TBL] [Abstract][Full Text] [Related]
18. The expression of miR-513c and miR-3163 was downregulated in tumor tissues compared with normal adjacent tissue of patients with breast cancer.
Delgir S; Ilkhani K; Safi A; Rahmati Y; Montazari V; Zaynali-Khasraghi Z; Seif F; Bastami M; Alivand MR
BMC Med Genomics; 2021 Jul; 14(1):180. PubMed ID: 34233668
[TBL] [Abstract][Full Text] [Related]
19. Meta-microRNA Biomarker Signatures to Classify Breast Cancer Subtypes.
Oztemur Islakoglu Y; Noyan S; Aydos A; Gur Dedeoglu B
OMICS; 2018 Nov; 22(11):709-716. PubMed ID: 30388053
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of microRNA-19b in hormone receptor-positive/HER2-negative breast cancer.
Maleki E; Ghaedi K; Shahanipoor K; Karimi Kurdistani Z
APMIS; 2018 Apr; 126(4):303-308. PubMed ID: 29575198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
